Enterprise Value
129.2M
Cash
448.7M
Avg Qtr Burn
-59.43M
Short % of Float
28.25%
Insider Ownership
22.23%
Institutional Own.
72.95%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALLO-647 (Anti-CD52 mAb) Details Cancer, Diffuse large B cell lymphoma | Phase 3 Initiation | |
Cemacabtagene ansegedleucel, or cema-cel [ALLO-501A (CD19)] Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
ALLO-647 (Anti-CD52 mAb) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
ALLO-316 (CD70) Details Renal cell carcinoma, Cancer, Solid tumor/s | Phase 1 Data readout | |
ALLO-715 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update | |
ALLO-605 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update |